Home Tags Prescription Drugs

Tag: Prescription Drugs

Tocilizumab may be beneficial for adults with COVID-19 admitted to the intensive care unit

Findings Conflicted for Benefit of Tocilizumab in COVID-19

One trial shows reduction in mortality, but no evidence of efficacy seen in two additional trials
Chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab is associated with a high incidence of molecular response and survival in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

Dasatinib + Blinatumomab Active for Ph-Positive ALL in Adults

Complete remission, overall survival seen in 98, 95 percent of patients in phase 2 study
For moderately ill hospitalized patients with COVID-19

Tocilizumab Does Not Prevent Intubation, Death in COVID-19

Intubation or death, disease worsening similar for tocilizumab, placebo in hospitalized patients
In 2017 to 2019

CDC: 65.3 Percent of U.S. Women Currently Using Contraceptives

Female sterilization most common contraceptive method; use declined with higher education
For about 20 percent of patients with neovascular age-related macular degeneration

Anti-VEGF Therapy May Aid Visual Acuity in Some nAMD Patients

Useful visual acuity preserved for about 20 percent of patients over their average remaining lifetime
Upadacitinib is superior to abatacept for patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs

Upadacitinib Tops Abatacept for RA Refractory to DMARDs

Superior for mean change in composite DAS28-CRP values and remission, but more adverse events seen
The U.S. Food and Drug Administration is requiring labeling changes to nonsteroidal anti-inflammatory drugs that warn of the risks of taking these drugs at 20 weeks of pregnancy or later

FDA Requiring Labeling Changes to NSAIDs Warning of Risks in Pregnancy

Labeling must indicate risks to unborn baby with NSAID use at 20 weeks of pregnancy or later
Ertugliflozin is noninferior to placebo with respect to major adverse cardiovascular events among patients with type 2 diabetes and atherosclerotic cardiovascular disease

Ertugliflozin Noninferior for CV Outcomes in T2DM With ASCVD

Ertugliflozin is noninferior to placebo for the primary end point of major adverse cardiovascular events
Polypharmacy

Polypharmacy Common in Seniors With Heart Failure

With increasing number of medications, more rapid increase seen in number of noncardiovascular meds
A study to assess whether certain approved or experimental drugs are effective against COVID-19 and warrant testing in large clinical trials has been launched by the U.S. National Institutes of Health (NIH).

NIH Launches Trial of Antibody Drugs Against COVID-19

The phase 2 trial will assess effectiveness of monoclonal antibodies in conjunction with remdesivir